As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
Researchers sought to determine the prognostic role of cytogenetics in Philadelphia-negative myeloproliferative neoplasms.
Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.
Researchers are conducting a phase 3 trial to investigate the safety and efficacy of parsaclisib and ruxolitinib vs placebo and ruxolitinib among patients with myelofibrosis who have displayed a suboptimal response to ruxolitinib only.
A geno-clinical model used mutational data and peripheral blood counts to accurately distinguish myelodysplastic syndromes from other myeloid malignancies.
Patients with myelofibrosis conditioned with 2 alkylating agents may have better transplant outcomes compared with patients receiving 1 alkylating agent.
Investigators summarized current literature surrounding the diagnosis and risk-stratification of PV and ET, and reviewed available and upcoming therapies.
Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.
Germline polymorphisms can affect response to treatment in people with polycythemia vera.
As transplantation-related complications are high among patients with MDS, determining which patients will benefit from HSCT is essential.
